IL138214A0
(en)
|
1998-03-09 |
2001-10-31 |
Zealand Pharmaceuticals As |
Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
SE9801571D0
(sv)
|
1998-05-05 |
1998-05-05 |
Wapharm Ab |
Melanokortin-1-receptorselektiva föreningar
|
US6444788B1
(en)
|
1999-03-15 |
2002-09-03 |
Novo Nordisk A/S |
Ion exchange chromatography of GLP-1, analogs and derivatives thereof
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
US7371721B2
(en)
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
EP1970072A1
(en)
|
2000-09-18 |
2008-09-17 |
Sanos Bioscience A/S |
Use of GLP-2 peptides for the treatment of hyperparathyroidism
|
CA2431173A1
(en)
|
2000-12-13 |
2002-06-20 |
Eli Lilly And Company |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
CN1162446C
(zh)
*
|
2001-05-10 |
2004-08-18 |
上海华谊生物技术有限公司 |
促胰岛素分泌肽衍生物
|
CN1158304C
(zh)
*
|
2001-05-10 |
2004-07-21 |
上海华谊生物技术有限公司 |
蛙皮抗菌肽衍生物
|
JP5562510B2
(ja)
|
2001-06-28 |
2014-07-30 |
ノヴォ ノルディスク アー/エス |
修飾glp−1の安定な処方剤
|
AU2002317599B2
(en)
|
2001-07-31 |
2008-04-03 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
GLP-1 exendin-4 peptide analogs and uses thereof
|
US7176278B2
(en)
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
US8129504B2
(en)
|
2001-08-30 |
2012-03-06 |
Biorexis Technology, Inc. |
Oral delivery of modified transferrin fusion proteins
|
AU2002332054B2
(en)
|
2001-09-24 |
2007-11-08 |
Imperial Innovations Limited |
Modification of feeding behavior
|
AU2002351752A1
(en)
|
2001-12-29 |
2003-07-30 |
Novo Nordisk A/S |
Combined use of a glp-1 compound and another drug for treating dyslipidemia
|
AU2003201998C1
(en)
|
2002-01-10 |
2012-10-25 |
Imperial Innovations Limited |
Modification of feeding behavior
|
US7105489B2
(en)
|
2002-01-22 |
2006-09-12 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating polycystic ovary syndrome
|
JP2005535569A
(ja)
*
|
2002-04-04 |
2005-11-24 |
ノボ・ノルデイスク・エー/エス |
Glp−1アゴニスト及び心臓血管合併症
|
ATE432289T1
(de)
|
2002-07-04 |
2009-06-15 |
Zealand Pharma As |
Glp-1 und behandlungsmethode für diabetes
|
WO2004022004A2
(en)
*
|
2002-09-06 |
2004-03-18 |
Bayer Pharmaceuticals Corporation |
Modified glp-1 receptor agonists and their pharmacological methods of use
|
US7273921B2
(en)
|
2002-09-25 |
2007-09-25 |
Novo Nordisk A/S |
Method for producing acylated peptides
|
RU2376314C2
(ru)
*
|
2002-10-02 |
2009-12-20 |
Зилэнд Фарма А/С |
Стабилизированные соединения эксендина-4
|
JPWO2004037859A1
(ja)
*
|
2002-10-11 |
2006-02-23 |
株式会社三和化学研究所 |
Glp−1誘導体及びその経粘膜吸収型製剤
|
US6818721B2
(en)
|
2002-12-02 |
2004-11-16 |
Rpo Pty Ltd. |
Process for producing polysiloxanes and use of the same
|
EP1688148A1
(en)
*
|
2002-12-03 |
2006-08-09 |
Novo Nordisk A/S |
Combination treatment using exendin-4 and thiazolidinediones
|
EP1569682A2
(en)
*
|
2002-12-03 |
2005-09-07 |
Novo Nordisk A/S |
Combination treatment using exendin-4 and thiazolidinediones
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
WO2004078777A2
(en)
*
|
2003-03-04 |
2004-09-16 |
Biorexis Pharmaceutical Corporation |
Dipeptidyl-peptidase protected proteins
|
DE10314610A1
(de)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
WO2005000222A2
(en)
|
2003-05-30 |
2005-01-06 |
Amylin Pharmaceuticals, Inc. |
Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
US7008957B2
(en)
|
2003-07-25 |
2006-03-07 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
|
US7094800B2
(en)
|
2003-07-25 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Cyanopyrrolidides, process for their preparation and their use as medicaments
|
US7094794B2
(en)
|
2003-07-28 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
|
DE10335092B3
(de)
|
2003-08-01 |
2005-02-03 |
Aventis Pharma Deutschland Gmbh |
Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
|
EP1667724A2
(en)
*
|
2003-09-19 |
2006-06-14 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
CN101380476A
(zh)
*
|
2003-09-19 |
2009-03-11 |
诺沃挪第克公司 |
治疗肽的清蛋白结合型衍生物
|
WO2005027978A2
(en)
*
|
2003-09-19 |
2005-03-31 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
ES2373660T3
(es)
*
|
2003-11-13 |
2012-02-07 |
Novo Nordisk A/S |
Composición farmacéutica que comprende un análogo insulinotrópico de glp-1 (7-37), insulina asp(b28) y un tensioactivo.
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
KR101243648B1
(ko)
|
2003-11-20 |
2013-03-14 |
노보 노르디스크 에이/에스 |
제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
|
EP2298337B1
(en)
|
2003-12-09 |
2017-02-22 |
Novo Nordisk A/S |
Regulation of food preference using GLP-1 agonists
|
EP1701731A4
(en)
*
|
2003-12-12 |
2009-08-05 |
Einstein Coll Med |
GLP-1 (9-36): METHODS AND COMPOSITIONS
|
DE602004026113D1
(de)
|
2003-12-18 |
2010-04-29 |
Novo Nordisk As |
Glp-1-verbindungen
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
AU2005211755B2
(en)
|
2004-02-11 |
2012-03-15 |
Amylin Pharmaceuticals, Llc |
Hybrid polypeptides with selectable properties
|
CN1318587C
(zh)
*
|
2004-04-30 |
2007-05-30 |
成都芝田生物工程有限公司 |
酰胺化Exendin-4多肽的重组制备方法
|
EP2316446A1
(en)
|
2004-06-11 |
2011-05-04 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using GLP-1 agonists
|
DE102004043153B4
(de)
*
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
AU2012202855B2
(en)
*
|
2004-09-03 |
2015-02-26 |
Philipps-Universitat Marburg |
GLP-1 and exendin related invention
|
WO2006037810A2
(en)
|
2004-10-07 |
2006-04-13 |
Novo Nordisk A/S |
Protracted glp-1 compounds
|
JP5107713B2
(ja)
*
|
2004-10-07 |
2012-12-26 |
ノヴォ ノルディスク アー/エス |
遅延性のエキセンディン−4化合物
|
JP5248113B2
(ja)
*
|
2004-11-12 |
2013-07-31 |
ノヴォ ノルディスク アー/エス |
ペプチドの安定な処方
|
DE102004058306A1
(de)
*
|
2004-12-01 |
2006-07-27 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
|
US8716221B2
(en)
|
2005-01-14 |
2014-05-06 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
CN100540565C
(zh)
*
|
2005-01-14 |
2009-09-16 |
无锡宏创医药科技有限公司 |
修饰的Exendins及其应用
|
AU2006213607A1
(en)
|
2005-02-11 |
2006-08-17 |
Amylin Pharmaceuticals, Llc |
GIP analog and hybrid polypeptides with selectable properties
|
JP2008531730A
(ja)
*
|
2005-03-04 |
2008-08-14 |
キュアーディーエム、インク. |
I型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物
|
TWI372629B
(en)
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
WO2006097535A2
(en)
*
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
WO2006097538A1
(en)
*
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Extended glp-1 compounds
|
UA95235C2
(en)
|
2005-05-04 |
2011-07-25 |
Зииланд Фарма А/С |
Glucagon-like-peptide-2 (glp-2) analogues
|
EP2295066B1
(en)
|
2005-05-25 |
2016-04-27 |
CureDM Group Holdings, LLC |
Peptides, derivatives and analogs thereof, and methods of using same
|
AU2006279680B2
(en)
|
2005-08-11 |
2012-12-06 |
Amylin Pharmaceuticals, Llc |
Hybrid polypeptides with selectable properties
|
EP2330125A3
(en)
|
2005-08-11 |
2012-12-12 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
RS52747B
(en)
|
2005-08-26 |
2013-08-30 |
Abbvie Inc. |
THERAPEUTIC ACTIVE ANALYSIS OF ALFA-MSH
|
DE102006031962A1
(de)
|
2006-07-11 |
2008-01-17 |
Sanofi-Aventis Deutschland Gmbh |
Amidiertes Insulin Glargin
|
DE102006031955A1
(de)
|
2006-07-11 |
2008-01-17 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
|
CN101511868B
(zh)
|
2006-07-24 |
2013-03-06 |
比奥雷克西斯制药公司 |
毒蜥外泌肽融合蛋白
|
WO2008017381A1
(de)
|
2006-08-08 |
2008-02-14 |
Sanofi-Aventis |
Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
|
BRPI0716134A2
(pt)
|
2006-09-07 |
2013-09-17 |
Nycomed Gmbh |
tratamento de combinaÇço para diabetes mellitus
|
CN101573376B
(zh)
|
2006-11-08 |
2013-11-06 |
西兰制药公司 |
选择性胰高血糖素样肽-2(glp-2)类似物
|
JP2010043001A
(ja)
*
|
2006-11-09 |
2010-02-25 |
Sanwa Kagaku Kenkyusho Co Ltd |
Glp−1誘導体とその用途
|
WO2008064306A2
(en)
|
2006-11-22 |
2008-05-29 |
Curedm, Inc. |
Methods and compositions relating to islet cell neogenesis
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
RU2413528C2
(ru)
|
2007-01-18 |
2011-03-10 |
Открытое Акционерное Общество "Валента Фармацевтика" |
Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
|
DE102007005045B4
(de)
|
2007-01-26 |
2008-12-18 |
Sanofi-Aventis |
Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
WO2008098693A2
(en)
*
|
2007-02-16 |
2008-08-21 |
Bayer Healthcare Ag |
Convergent synthesis of glp-1
|
MX2009013354A
(es)
|
2007-06-04 |
2010-07-06 |
Univ Ben Gurion |
Compuestos de triarilo y composiciones que los contienen.
|
ATE520714T1
(de)
|
2007-06-15 |
2011-09-15 |
Zealand Pharma As |
Glucagonanaloga
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
CN101896499B
(zh)
|
2007-08-30 |
2014-02-12 |
库尔Dm股份有限公司 |
使用前胰岛肽及其类似物的组合物和方法
|
CN101842386A
(zh)
|
2007-09-05 |
2010-09-22 |
诺沃-诺迪斯克有限公司 |
截短的glp-1衍生物和它们的治疗用途
|
WO2009030738A1
(en)
*
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
WO2009053315A1
(en)
*
|
2007-10-27 |
2009-04-30 |
F. Hoffmann-La Roche Ag |
Insulinotropic peptide synthesis using solid and solution phase combination techniques
|
DE102007054497B3
(de)
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
MX2010005245A
(es)
|
2007-11-16 |
2010-06-01 |
Novo Nordisk As |
Composiciones farmaceuticas que comprenden peptidos glp-1 o exendin-4 y un peptido de insulina basal.
|
DE102008003566A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
DE102008025008A1
(de)
|
2008-05-24 |
2009-11-26 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
DE102008025007A1
(de)
|
2008-05-24 |
2009-11-26 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
DE102008003568A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
DK2229407T3
(da)
|
2008-01-09 |
2017-02-27 |
Sanofi Aventis Deutschland |
Nye insulinderivater med ekstremt forsinket tids-/virkningsprofil
|
AU2009203810B2
(en)
|
2008-01-09 |
2013-07-25 |
Sanofi-Aventis Deutschland Gmbh |
Novel insulin derivatives having an extremely delayed time-action profile
|
US9062124B2
(en)
*
|
2008-06-17 |
2015-06-23 |
Indiana University Research And Technology Corporation |
GIP-based mixed agonists for treatment of metabolic disorders and obesity
|
EP3412300A1
(en)
|
2008-06-27 |
2018-12-12 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
AR072707A1
(es)
|
2008-07-09 |
2010-09-15 |
Sanofi Aventis |
Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
|
AU2009279090A1
(en)
|
2008-08-06 |
2010-02-11 |
Novo Nordisk Health Care Ag |
Conjugated proteins with prolonged in vivo efficacy
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
DE102009038210A1
(de)
|
2009-08-20 |
2011-03-03 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
DE102008051834A1
(de)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
MX344293B
(es)
|
2008-10-17 |
2016-12-13 |
Sanofi Aventis Deutschland |
Combinacion de una insulina y un agonista de glp-1.
|
ES2614427T3
(es)
|
2008-11-07 |
2017-05-31 |
The General Hospital Corporation |
Fragmentos C-terminales de péptido glucagonoide 1 (GLP-1)
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
HUE031900T2
(en)
*
|
2008-12-10 |
2017-08-28 |
Glaxosmithkline Llc |
Pharmaceutical compositions containing Albiglutide
|
US8680049B2
(en)
|
2008-12-15 |
2014-03-25 |
Zealand Pharma A/S |
Glucagon analogues
|
EA020537B1
(ru)
|
2008-12-15 |
2014-11-28 |
Зилэнд Фарма А/С |
Аналоги глюкагона
|
EP2370461B1
(en)
|
2008-12-15 |
2013-10-02 |
Zealand Pharma A/S |
Glucagon analogues
|
AU2008365556A1
(en)
|
2008-12-15 |
2011-07-21 |
Zealand Pharma A/S |
Glucagon analogues
|
JP5816097B2
(ja)
|
2009-01-22 |
2015-11-18 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
安定な成長ホルモン化合物
|
MY159865A
(en)
*
|
2009-07-06 |
2017-02-15 |
Sanofi Aventis Deutschland |
Aqueous insulin preparations containing methionine
|
WO2011003823A1
(de)
*
|
2009-07-06 |
2011-01-13 |
Sanofi-Aventis Deutschland Gmbh |
Langsamwirkende insulinzubereitungen
|
AU2010272944B2
(en)
|
2009-07-13 |
2015-11-19 |
Zealand Pharma A/S |
Acylated glucagon analogues
|
CN101987868B
(zh)
*
|
2009-07-30 |
2013-09-04 |
江苏豪森医药集团有限公司 |
Glp-1类似物的衍生物或其可药用盐和用途
|
US8841249B2
(en)
|
2009-08-06 |
2014-09-23 |
Novo Nordisk A/S |
Growth hormones with prolonged in-vivo efficacy
|
WO2011023754A1
(en)
|
2009-08-26 |
2011-03-03 |
Sanofi-Aventis |
Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
|
US20120264685A1
(en)
|
2009-10-22 |
2012-10-18 |
Rajesh Bahekar |
Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
|
DE102010011919A1
(de)
|
2010-03-18 |
2011-09-22 |
Sanofi-Aventis Deutschland Gmbh |
Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten und Methionin
|
AU2009238272B2
(en)
*
|
2009-11-13 |
2014-05-08 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to metformin
|
HUE026489T2
(en)
|
2009-11-13 |
2016-06-28 |
Sanofi Aventis Deutschland |
Combination of lixisenatide and metformin to treat type 2 diabetes
|
PL2329848T5
(pl)
|
2009-11-13 |
2019-12-31 |
Sanofi-Aventis Deutschland Gmbh |
Liksysenatyd z insuliną glargine i metforminą jako terapia skojarzona do leczenia cukrzycy typu 2
|
BR112012011403B8
(pt)
|
2009-11-13 |
2021-05-25 |
Sanofi Aventis Deutschland |
composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
|
PT2498802E
(pt)
|
2009-11-13 |
2015-04-13 |
Sanofi Aventis Deutschland |
Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
|
JP2011105609A
(ja)
*
|
2009-11-13 |
2011-06-02 |
Sanofi-Aventis Deutschland Gmbh |
メトホルミンへの付加療法を含む2型糖尿病の治療方法
|
NZ601167A
(en)
|
2010-01-20 |
2014-12-24 |
Zealand Pharma As |
Treatment of cardiac conditions
|
AU2011208620B2
(en)
|
2010-01-22 |
2015-04-16 |
Novo Nordisk Health Care Ag |
Stable growth hormone compounds
|
AU2011208625C1
(en)
|
2010-01-22 |
2022-08-18 |
Novo Nordisk Health Care Ag |
Growth hormones with prolonged in-vivo efficacy
|
US9422330B2
(en)
|
2010-03-01 |
2016-08-23 |
Novo Nordisk A/S |
Preparative RP-HPLC method for purifying peptides
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2555791B1
(en)
|
2010-04-09 |
2017-11-01 |
Sinai Health System |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
DE102010015123A1
(de)
|
2010-04-16 |
2011-10-20 |
Sanofi-Aventis Deutschland Gmbh |
Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
JP5969461B2
(ja)
|
2010-04-27 |
2016-08-17 |
ジーランド ファーマ アクティーゼルスカブ |
Glp−1受容体作動薬とガストリンとのペプチド複合体及びその使用
|
EP2566502A4
(en)
|
2010-05-04 |
2013-10-09 |
Glaxosmithkline Llc |
METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
EP2389945A1
(en)
|
2010-05-28 |
2011-11-30 |
Sanofi-Aventis Deutschland GmbH |
Pharmaceutical composition comprising AVE0010 and insulin glargine
|
CN101891823B
(zh)
*
|
2010-06-11 |
2012-10-03 |
北京东方百泰生物科技有限公司 |
一种Exendin-4及其类似物融合蛋白
|
US8933024B2
(en)
|
2010-06-18 |
2015-01-13 |
Sanofi |
Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
AR081975A1
(es)
|
2010-06-23 |
2012-10-31 |
Zealand Pharma As |
Analogos de glucagon
|
EA201291234A1
(ru)
|
2010-06-24 |
2013-07-30 |
Зилэнд Фарма А/С |
Аналоги глюкагона
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
RU2546520C2
(ru)
|
2010-08-30 |
2015-04-10 |
Санофи-Авентис Дойчланд Гмбх |
Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
|
WO2012061466A2
(en)
|
2010-11-02 |
2012-05-10 |
The General Hospital Corporation |
Methods for treating steatotic disease
|
HUE036066T2
(hu)
|
2010-12-16 |
2018-06-28 |
Novo Nordisk As |
GLP-1 agonistát és N-(8-(2-hidroxibenzoil)amino)kaprilsav sóját tartalmazó szilárd készítmények
|
TW201236692A
(en)
|
2011-02-02 |
2012-09-16 |
Sanofi Aventis Deutschland |
Prevention of hypoglycaemia in diabetes mellitus type 2 patients
|
EP2683704B1
(de)
|
2011-03-08 |
2014-12-17 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US8895547B2
(en)
|
2011-03-08 |
2014-11-25 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
US8828994B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
EP2683698B1
(de)
|
2011-03-08 |
2017-10-04 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
WO2012120050A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8901114B2
(en)
|
2011-03-08 |
2014-12-02 |
Sanofi |
Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
|
US8846666B2
(en)
|
2011-03-08 |
2014-09-30 |
Sanofi |
Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
EP2683699B1
(de)
|
2011-03-08 |
2015-06-24 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US20120277147A1
(en)
|
2011-03-29 |
2012-11-01 |
Sanofi-Aventis Deutschland Gmbh |
Prevention of hypoglycaemia in diabetes mellitus type 2 patients
|
PT2696687T
(pt)
|
2011-04-12 |
2017-02-02 |
Novo Nordisk As |
Derivados de glp-1 duplamente acilados
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
US8735349B2
(en)
|
2011-05-13 |
2014-05-27 |
Sanofi-Aventis Deutschland Gmbh |
Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L
|
US20130040878A1
(en)
|
2011-05-13 |
2013-02-14 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for use in the treatment of diabetes type 2 patients
|
JP6442284B2
(ja)
|
2011-05-13 |
2018-12-19 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
2型糖尿病の処置のためのリキシセナチド及びメトホルミン
|
EP2729157B1
(en)
|
2011-07-06 |
2019-01-16 |
The General Hospital Corporation |
A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
|
US9408893B2
(en)
|
2011-08-29 |
2016-08-09 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
WO2013050379A1
(en)
|
2011-10-04 |
2013-04-11 |
Sanofi-Aventis Deutschland Gmbh |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the pancreatic duct system
|
WO2013050378A1
(en)
|
2011-10-04 |
2013-04-11 |
Sanofi-Aventis Deutschland Gmbh |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
|
CA2851690C
(en)
|
2011-10-28 |
2022-07-26 |
Sanofi-Aventis Deutschland Gmbh |
Treatment protocol of diabetes type 2
|
CN103087174B
(zh)
*
|
2011-11-03 |
2015-11-18 |
华东师范大学 |
一种glp-1衍生物dlg3312及其固相化学合成方法
|
MX2014005351A
(es)
|
2011-11-03 |
2014-05-28 |
Zealand Pharma As |
Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
|
WO2013083826A2
(en)
|
2011-12-09 |
2013-06-13 |
Novo Nordisk A/S |
Glp-1 agonists
|
MX2014007120A
(es)
|
2011-12-23 |
2015-03-05 |
Boehringer Ingelheim Int |
Analogos de glucagon.
|
RU2641198C3
(ru)
|
2012-03-22 |
2021-12-10 |
Ново Нордиск А/С |
Композиции glp-1 пептидов и их получение
|
DK2827845T3
(da)
|
2012-03-22 |
2019-04-01 |
Novo Nordisk As |
Sammensætninger omfattende et fremføringsmiddel og fremstilling deraf
|
CA2872315A1
(en)
|
2012-05-03 |
2013-11-07 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (glp-2) analogues
|
CN104470948B
(zh)
|
2012-05-03 |
2018-06-15 |
西兰制药公司 |
Gip-glp-1双激动剂化合物及方法
|
EP2863895B1
(en)
|
2012-06-20 |
2021-04-14 |
Novo Nordisk A/S |
Tablet formulation comprising a peptide and a delivery agent
|
CA2878991C
(en)
|
2012-07-23 |
2021-12-07 |
Zealand Pharma A/S |
Glucagon analogues
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
IN2015DN03795A
(da)
|
2012-10-24 |
2015-10-02 |
Inserm Inst Nat De La Santé Et De La Rech Médicale |
|
WO2014077575A1
(ko)
*
|
2012-11-13 |
2014-05-22 |
다인바이오 주식회사 |
덱에이 효소반응으로 조제한 항비만 및 항당뇨 효능을 갖는 한천 유래 네오아가로올리고당 복합 조성물
|
KR20140088837A
(ko)
|
2013-01-03 |
2014-07-11 |
한미약품 주식회사 |
N-말단 전하가 변형된 인슐린 분비 펩티드 유도체
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
CA2907848A1
(en)
|
2013-04-03 |
2014-10-09 |
Sanofi |
Treatment of diabetes mellitus by long-acting formulations of insulins
|
CN105120887A
(zh)
|
2013-04-05 |
2015-12-02 |
诺和诺德保健股份有限公司 |
生长激素化合物制剂
|
CN105377884B
(zh)
*
|
2013-07-04 |
2021-07-20 |
诺和诺德股份有限公司 |
Glp-1样肽的衍生物和其用途
|
GB201315335D0
(en)
|
2013-08-29 |
2013-10-09 |
Of Singapore |
Amino diacids containing peptide modifiers
|
US9988429B2
(en)
*
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
AR098065A1
(es)
|
2013-10-17 |
2016-04-27 |
Zealand Pharma As |
Análogos de glucagón acilados
|
AU2014347668A1
(en)
|
2013-11-05 |
2016-05-19 |
Ben-Gurion University Of The Negev Research And Development Authority |
Compounds for the treatment of diabetes and disease complications arising from same
|
EA035688B1
(ru)
|
2013-11-06 |
2020-07-27 |
Зилэнд Фарма А/С |
Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
|
WO2015067715A2
(en)
|
2013-11-06 |
2015-05-14 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
CN103613657B
(zh)
*
|
2013-11-28 |
2016-01-13 |
孙玉琨 |
缩短肽链的Exendin4及其基因工程应用
|
SG11201604708VA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
WO2015104314A1
(en)
|
2014-01-09 |
2015-07-16 |
Sanofi |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
CN105899190B
(zh)
|
2014-01-09 |
2022-06-14 |
赛诺菲 |
门冬胰岛素的稳定化药物制剂
|
KR101768446B1
(ko)
|
2014-03-21 |
2017-08-17 |
애니젠 주식회사 |
신규한 엑세나타이드 유사체 및 그의 용도
|
EP3985016A1
(en)
|
2014-10-29 |
2022-04-20 |
Zealand Pharma A/S |
Gip agonist compounds and methods
|
LT3229828T
(lt)
|
2014-12-12 |
2023-06-12 |
Sanofi-Aventis Deutschland Gmbh |
Insulino glargino/liksisenatido fiksuoto santykio kompozicija
|
TWI706779B
(zh)
|
2015-01-16 |
2020-10-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
小兒第2型糖尿病病患之治療
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
US10426818B2
(en)
|
2015-03-24 |
2019-10-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Method and pharmaceutical composition for use in the treatment of diabetes
|
KR20170137198A
(ko)
|
2015-04-16 |
2017-12-12 |
질랜드 파마 에이/에스 |
아실화된 글루카곤 유사체
|
SG11201903938XA
(en)
|
2016-12-09 |
2019-05-30 |
Zealand Pharma As |
Acylated glp-1/glp-2 dual agonists
|
TWI791539B
(zh)
|
2017-06-16 |
2023-02-11 |
丹麥商西蘭製藥公司 |
用於投予類升糖素胜肽-2(glp-2)類似物的給藥方案
|
DK4019039T3
(da)
|
2017-07-27 |
2024-01-15 |
Adocia |
Sammensætninger i form af en injicerbar vandig opløsning, som omfatter mindst et humant insulin A21G og en glucagonundertrykker med prandial virkning
|
FR3082426A1
(fr)
|
2018-06-14 |
2019-12-20 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
|
CN111050750A
(zh)
|
2017-08-24 |
2020-04-21 |
诺沃挪第克公司 |
Glp-1组合物及其用途
|
PE20210453A1
(es)
|
2018-02-02 |
2021-03-08 |
Novo Nordisk As |
Composiciones solidas que comprenden un agonista de glp-1, una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante
|
SG11202010016QA
(en)
|
2018-04-10 |
2020-11-27 |
Sanofi Aventis Deutschland |
Lixisenatide synthesis with capping
|
MX2020010716A
(es)
|
2018-04-10 |
2021-03-09 |
Sanofi Aventis Deutschland |
Metodo para escindir de la fase solida peptidos unidos a una fase solida.
|
FR3083700B1
(fr)
|
2018-07-13 |
2021-03-12 |
Adocia |
Formulation thermostable d'insuline humaine a21g
|
EP3628683A1
(en)
|
2018-09-28 |
2020-04-01 |
Zealand Pharma A/S |
Formulations of glucagon-like-peptide-2 (glp-2) analogues
|
EP3628682A1
(en)
|
2018-09-28 |
2020-04-01 |
Zealand Pharma A/S |
Formulations of glucagon-like-peptide-2 (glp-2) analogues
|
TWI799680B
(zh)
*
|
2019-01-29 |
2023-04-21 |
美商美國禮來大藥廠 |
製備gip/glp1雙重促效劑之方法
|
CN109721653B
(zh)
*
|
2019-03-05 |
2023-02-03 |
嘉兴学院 |
一种胰高血糖素样肽-1片段类似物及其应用
|
US20210093698A1
(en)
|
2019-09-13 |
2021-04-01 |
Sanofi |
Treatment of type 2 diabetes mellitus
|
EP3858373A1
(en)
|
2020-01-31 |
2021-08-04 |
Adocia |
Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
|
MX2022009523A
(es)
|
2020-02-18 |
2022-09-09 |
Novo Nordisk As |
Formulaciones farmaceuticas.
|
EP3915572A1
(en)
|
2020-05-29 |
2021-12-01 |
Adocia |
Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
|
EP3915571A1
(en)
|
2020-05-29 |
2021-12-01 |
Adocia |
Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
|
MX2023006811A
(es)
*
|
2020-12-11 |
2023-07-12 |
Ip2Ipo Innovations Ltd |
Compuestos novedosos.
|
EP4129324A1
(en)
|
2021-08-02 |
2023-02-08 |
Adocia |
Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
|
CA3231402A1
(en)
|
2021-09-10 |
2023-03-16 |
Eva Horn Moller |
Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues
|
WO2023118416A1
(en)
|
2021-12-23 |
2023-06-29 |
Zealand Pharma A/S |
Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues
|
WO2024068848A1
(en)
|
2022-09-28 |
2024-04-04 |
Zealand Pharma A/S |
Methods for treating obesity
|